Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Saunders

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Journal for Immunotherapy of Cancer|December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
World Journal of Surgery|April 24, 2024
Cytoreductive surgery plus hyperthermic intraoperative peritoneal chemotherapy for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomized controlled trialsKurinchi Gurusamy, Jeffrey Leung, Claire Vale, et al.
British Journal of Cancer|August 18, 2018
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUSSimon Gollins, Nicholas West, David Sebag-Montefiore, et al.
Health Technology Assessment (Winchester, England)|September 10, 2024
Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysisKurinchi Gurusamy, Jeffrey Leung, Claire Vale, et al.
Clinical Colorectal Cancer|January 1, 2021
The Impact of Changes in Service Delivery in Patients With Colorectal Cancer During the Initial Phase of the COVID-19 PandemicKonstantinos Kamposioras, Mark Saunders, Kok Haw Jonathan Lim, et al.
Cancer Research|May 23, 2002
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factorGisele Höpfl, Roland H Wenger, Urs Ziegler, et al.
The Lancet. Oncology|January 18, 2017
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyTamas Hickish, Thierry Andre, Lucjan Wyrwicz, et al.
Clinical Colorectal Cancer|January 12, 2025
Oncological Outcomes From Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal MetastasesNadina Tinsley, Sarah T O'Dwyer, Raghavendar Nagaraju, et al.
Clinical Colorectal Cancer|December 26, 2021
Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal CancerKonstantinos Kamposioras, Kok Haw Jonathan Lim, Joseph Williams, et al.
International Journal of Colorectal Disease|January 8, 2026
Exploring perceptual disparities: A study on the level of understanding of colorectal cancer care among patients and healthcare professionalsEleftherios Christodoulis, Panagiotis Ntellas, Lilly Simpson, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Journal for Immunotherapy of Cancer|December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
World Journal of Surgery|April 24, 2024
Cytoreductive surgery plus hyperthermic intraoperative peritoneal chemotherapy for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomized controlled trialsKurinchi Gurusamy, Jeffrey Leung, Claire Vale, et al.
British Journal of Cancer|August 18, 2018
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUSSimon Gollins, Nicholas West, David Sebag-Montefiore, et al.
Health Technology Assessment (Winchester, England)|September 10, 2024
Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysisKurinchi Gurusamy, Jeffrey Leung, Claire Vale, et al.
Clinical Colorectal Cancer|January 1, 2021
The Impact of Changes in Service Delivery in Patients With Colorectal Cancer During the Initial Phase of the COVID-19 PandemicKonstantinos Kamposioras, Mark Saunders, Kok Haw Jonathan Lim, et al.
Cancer Research|May 23, 2002
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factorGisele Höpfl, Roland H Wenger, Urs Ziegler, et al.
The Lancet. Oncology|January 18, 2017
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 studyTamas Hickish, Thierry Andre, Lucjan Wyrwicz, et al.
Clinical Colorectal Cancer|January 12, 2025
Oncological Outcomes From Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal MetastasesNadina Tinsley, Sarah T O'Dwyer, Raghavendar Nagaraju, et al.
Clinical Colorectal Cancer|December 26, 2021
Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal CancerKonstantinos Kamposioras, Kok Haw Jonathan Lim, Joseph Williams, et al.
International Journal of Colorectal Disease|January 8, 2026
Exploring perceptual disparities: A study on the level of understanding of colorectal cancer care among patients and healthcare professionalsEleftherios Christodoulis, Panagiotis Ntellas, Lilly Simpson, et al.
Pageof 9